Abliva Announces CEO Changes, with Effect from February 3rd
January 21, 2021 at 12:30 am IST
Abliva AB announced that the Board of Directors, in agreement with Dr. Erik Kinnman, the current CEO, has appointed Dr. Ellen K. Donnelly, Ph.D. as the company's new CEO to lead Abliva's development into a commercial biopharmaceutical company. Dr. Donnelly succeeds Dr. Erik Kinnman, around February 3rd. Most recently, Ellen was CEO of the Division of Epigenetics at Juvenescence and CEO for its subsidiary company, Souvien Therapeutics.